TY - JOUR
T1 - Alopecia in Children Following Living Related Liver Transplantation
AU - Alatas, Fatima Safira
AU - Matsuura, Toshiharu
AU - Yoshimaru, Koichiro
AU - Kadim, Muzal
AU - Taguchi, Tomoaki
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Introduction: Alopecia is a common complication in patients following kidney transplantation; however, reports regarding liver transplantation patients are still few. Methods: This study followed 111 children who underwent living related liver transplantation. Alopecia patients and its possible risk factors were analyzed. Results: Alopecia occurred in 3 patients (2.7%). Underlying diseases were biliary atresia and Alagille syndrome. Clinically significant alopecia (universal alopecia) occurred in 1 patient with Alagille syndrome. All patients received tacrolimus as their immunosuppression drug. None of the patients who received cyclosporine experienced alopecia. The onset of alopecia ranged from 7 to 28 months after transplantation. Alopecia was treated with a topical corticosteroid and topical tacrolimus, but 1 patient with clinically severe alopecia required conversion from tacrolimus to cyclosporine A. Conclusions: Alopecia is 1 complication seen in children receiving tacrolimus therapy following living donor liver transplant. Prompt management of this cosmetic complication should be done to ensure patients’ compliance to medication regimen.
AB - Introduction: Alopecia is a common complication in patients following kidney transplantation; however, reports regarding liver transplantation patients are still few. Methods: This study followed 111 children who underwent living related liver transplantation. Alopecia patients and its possible risk factors were analyzed. Results: Alopecia occurred in 3 patients (2.7%). Underlying diseases were biliary atresia and Alagille syndrome. Clinically significant alopecia (universal alopecia) occurred in 1 patient with Alagille syndrome. All patients received tacrolimus as their immunosuppression drug. None of the patients who received cyclosporine experienced alopecia. The onset of alopecia ranged from 7 to 28 months after transplantation. Alopecia was treated with a topical corticosteroid and topical tacrolimus, but 1 patient with clinically severe alopecia required conversion from tacrolimus to cyclosporine A. Conclusions: Alopecia is 1 complication seen in children receiving tacrolimus therapy following living donor liver transplant. Prompt management of this cosmetic complication should be done to ensure patients’ compliance to medication regimen.
UR - http://www.scopus.com/inward/record.url?scp=85086940620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086940620&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2020.05.020
DO - 10.1016/j.transproceed.2020.05.020
M3 - Article
C2 - 32605770
AN - SCOPUS:85086940620
SN - 0041-1345
VL - 53
SP - 228
EP - 232
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 1
ER -